Baxter International Inc. has entered an agreement to acquire Chatham Therapeutics for an initial payment of $70 million, and potential future payments based on certain development, regulatory and commercial milestones. With the acquisition, Baxter gains Chatham’s developmental gene therapy programs for the development and commercialization of treatments for hemophilia.   The two companies entered a collaboration in May 2012 to evaluate Chatham’s Biological Nano Particle (BNP) platform for poten...